Objective: To determine if short term (2 week) treatment of growing male rats with low levels of dehydroepiandrosterone-sulfate (DHEAS) can reduce adiposity and serum triglycerides. Design: Rats were administered either normal drinking water or drinking water supplemented with 10 (D10) or 100 (D100) mg/ml DHEAS for 14 d. Subjects: Twenty-one male Sprague-Dawley rats (initial body weight 280 g). Measurements: Adipocyte mass, size and number from three major fat depots (retroperitoneal, epididymal, inguinal); serum levels of triglycerides, insulin, IGF-1 and DHEAS; brown adipose tissue (BAT) mass, uncoupling protein content and enzyme activity; body weight gain, food and water consumption; carcass composition. Results: DHEAS treatment had no effect on weight gain, food consumption or water intake. In contrast, rats treated with both levels of DHEAS had lighter fat pads, fewer epididymal and retroperitoneal adipocytes, less carcass lipid, lower levels of serum triglycerides and greater BAT mass and UCP content than control rats. Moreover, rats administered 100 mg/ml DHEAS had smaller and fewer epididymal adipocytes and fewer inguinal adipocytes than the D10 and the control rats. Conclusion: Acute treatment of growing male rats with low levels (10 mg/ml drinking water or 0.7 mg/kg body wt/d) of DHEAS reduces carcass lipid, adipose tissue mass and cellularity as well as serum triglycerides without altering food intake and body weight gain or causing hepatomegaly.
Introduction
The adrenal hormone dehydroepiandrosterone sulfate (DHEAS) is the most abundant steroid in the plasma of humans. 1, 2 Plasma levels of DHEAS are 200 fold greater than DHEA, the unsulfated and intracellular form of the steroid in humans. 2 Target tissues such as gonads, skin, macrophages and adipose possessing DHEAS sulfatase activity, convert DHEAS to DHEA.
2±6 Plasma levels of both DHEAS and DHEA decrease steadily as adults age. 1 This age-related decline in DHEAS has been inversely correlated with a number of age-related diseases, including atherosclerosis, 7 NIDDM, 8 and obesity. 9, 10 In light of this inverse relationship between DHEA(S) and adiposity, maintaining`youthful' or higher levels of DHEA(S) may prevent or be used to treat adiposity. In support of this hypothesis, several studies have found a signi®cant correlation between lower concentrations of DHEA(S) and higher levels of adiposity in both men 11, 12 and women. 13±15 Furthermore, low plasma levels of DHEAS have been inversely related to mortality among men; 16 the same was not found for women. 17 Moreover, several clinical trials have demonstrated that DHEA treatment reduces body fat 18, 19 and increases lean body mass 19 and muscle strength 20, 21 in mature adults. It is not known if DHEAS or DHEA levels decline during aging in the rat as they do in humans. Moreover, serum levels of DHEAS and DHEA are manyfold lower in rats 22±24 than in humans. 1, 2 This does not appear to be due to species differences in synthesis of DHEAS in the adrenal cortex since it has been demonstrated that rats secrete DHEAS almost exclusively from the adrenal glands and that this secretion, like that in humans, is stimulated by ACTH. 23 When administered at pharmacological levels to rodents (0.4±0.6% in the diet or 100 mg/kg body wt, i.p.), DHEA has antiobesity, antidiabetic properties that oppose the lipogenic actions of insulin and the glucocorticoids. 8±10 Whether supplied in the diet or administered orally or intraperitoneally, pharmacological levels of DHEA have been effective in reducing fat synthesis and fat mass in genetically obese rodents and in rodents in which lipogenesis has been induced. 25±38 DHEA treatment at pharmacological levels increases resting metabolic rate 29, 30, 35 and the relative amount of body protein 30, 33, 36 at the expense of body fat in normal rats. 20, 30, 33, 34 As a antihyperlipi-demic agent, exogenous DHEA lowers serum levels of triglcyerides 25, 33, 36 and total and LDL cholesterol. 25, 32, 36 In the aforementioned studies, treatment of humans and animals with high doses of DHEA has been shown to prevent and/or attenuate adiposity. However, enthusiasm for clinical use of DHEA has been dampened because of potential: (1) Therefore, we wondered if these low levels of DHEAS would attenuate adiposity in rats. Based on the work of Daynes et al, 43±45 this study examined the effects of DHEAS on carcass lipid and the weight and cellularity of three major fat pads in rats. Growing male Sprague-Dawley rats fed a high carbohydrate (64% of kcals), low fat (11% of kcals) diet were given DHEAS for 14 d in their drinking water at either 10 mg DHEAS/ml or 100 mg DHEAS/ml.
Materials and methods

Animals
Twenty-one male Sprague-Dawley rats (Charles Rivers Labs, Wilmington, DE), 7 weeks of age, were individually housed in stainless steel suspended cages with wire mesh bottoms. The room was controlled for temperature (21 AE 2 C), humidity (45± 50%), and light (lights on from 6 am to 6 pm). Animals were cared for in accordance with guidelines established by the Institute of Animal Resources of the National Research Council and their use in this experiment was approved by the IACUC Committee of the University of North Carolina at Greensboro.
All animals were provided an AIN 76A semipuri®ed diet (Table 1 ) ad libitum during acclimation to the animal facility and throughout the study. Body weight and food intake were measured on alternate days. At the end of the 14 d study, naso-anal length and the weight of several tissues were measured, and tissue samples taken for subsequent analyses. Blood was collected by cardiac puncture. Rats were in the non-fasted state when killed. Diet ingredients were purchased from US Biochemical, Cleveland, OH. All other chemicals and commercial kits were purchased from Sigma Chemical Co., St. Louis, MO, unless otherwise indicated.
Experimental design
The animals were randomly assigned to one of three treatment groups (n 7 per group) as follows: control (given distilled drinking water); D10 (given distilled drinking water supplemented with 10 mg of DHEAS/ ml); and D100 (given distilled drinking water supplemented with 100 mg DHEAS/ml). All animals were provided their drinking water ad libitum in 100 ml graduated water bottles which were replaced every two days. Water consumption was measured daily to determine DHEAS intakes.
On day 10, the rats were anesthetized with an intraperitoneal injection (i.p.) of ketamine-xylazine (80:10 mg/kg). They then received an i.p. injection of 7.5 ml of a 10% solution of sterile Brewer thioglycollate medium (Difco Labs, Detroit, MI) through a 10 ml syringe ®tted with a 23-gauge needle to elicit macrophages in the peritoneal cavity. Macrophages were harvested on day 14 and used in another study.
Collection of fat pads and sera
On day 14, non-fasted rats were anesthetized with an intramuscular injection of ketamine-xylazine-promazine (30:6:1 mg/kg body wt for control rats). Rats treated with the highest level of DHEAS (D100) were more resistant to the anesthesia, and therefore were given 1.5±2.0 times more anesthesia than the control animals. Following the removal of peritoneal macrophages, the retroperitoneal, epididymal, and inguinal fat pads from both sides of each rat were quantitatively removed and weighed. Interscapular brown adipose tissue (BAT) was removed, cleaned of adhering muscle, weighed and stored at 770 C for the determination of uncoupling protein (UCP) content and succinate cytochrome C reductase activity. Following removal of the inguinal fat pads, blood was collected from the right atrium by cardiac puncture using safety-monovette blood collecting tubes containing serum clotting activator (Sarstedt, Newton, NC). After resting on ice for 30 min, sera were collected by centrifugation at 1500 6 g for 20 min at 4 C. Sera were then stored at 720 C for determination of DHEAS, insulin-like growth factor one (IGF-1), insulin, and triglycerides.
Determination of cell number and size
After removal of each fat pad, the fat cells were isolated by collagenase digestion and counted. 46 Brie¯y, a representative sample of one gram of fat from each depot was washed in Krebs-Ringer-Hepes (KR-Hepes) buffer containing 2% bovine serum albumin (BSA) (wt/vol), pH 7.4, minced with scissors, and enzymatically digested with previously tested Type 1 collagenase (Worthington Biochemical Corp., Freehold, NJ) (2 mg/ml in 25 ml polypropylene Erlenmeyer¯asks). The¯asks were then incubated at 37 C in a shaker water bath at 20 cycles/min for 45±60 min. The resulting digest was then ®ltered over a 1000 mm polypropylene mesh screen (Spectrum, Houston, TX) and collected into a 50 ml polyethylene centrifuge tube. The collagenase was washed from the cells using 20 ml of collagenase-free KR-Hepes buffer with 2% BSA. The cells were allowed to¯oat for 5± 7 min, and the infranatant removed by aspiration; this procedure was repeated twice. After the ®nal wash, all but 0.5 ml of the infranatant was removed and duplicate samples of the resulting cells from each fat depot per animal were diluted 1:2 with Rappaport's stain and counted using a hemocytometer. Adipocyte diameter was determined by measuring the diameter of approximately 100±150 cells using an eyepiece micrometer on an Olympus inverted microscope.
Determination of brown adipose tissue (BAT) activity
The level of uncoupling protein (UCP) in crude homogenates of thawed BAT was determined. A representative 400 mg piece of tissue was ®rst cleaned a second time to remove any remaining muscle or white adipose tissue. This BAT was then placed in ice cold buffer (0.25 M sucrose; 1 mM Hepes, 0.2 mM EDTA), pH 7.2 and homogenized using a motor driven Te¯on-glass homogenizer. The protein content of this crude homogenate was determined using a commercially available kit (Bio-Rad Protein Assay; Bio-Rad Labs, Richmond, CA). Approximately 7.5 mg of crude homogenate BAT protein was run in each lane in a 10% SDS-PAGE pre-cast gel (Bio-Rad Labs). Approximately 0.1 mg of pure mouse UCP (generously provided by Dr. J. Himms-Hagen) was run in one lane of the gel. UCP was detected using rabbit, anti-hamster UCP antibody (generously provided by Dr. J. Himms-Hagen) and an enhanced chemiluminescence (ECL) Western blotting detection system (Amersham Corp., Arlington, IL). The bands were quanti®ed by standard densitometry using a BioRad Labs densitometer. Since the amount of white adipose tissue removed from the BAT was not recorded, the amount of UCP was expressed per mg of BAT protein instead of per BAT depot mass.
The activity of the inner mitochondrial membrane marker succinate cytochrome C reductase (succinate iodonitrotetrazolium [INT] reductase) was measured in the same crude BAT homogenate obtained for UCP. Succinate-INT-reductase activity was determined by incubating BAT homogenate with sodium succinate and INT formazan as previously described. 47 After the reaction was terminated by the addition of ethyl acetate, ethanol and trichloroacetic acid 5:5:1, vol:vol:weight), the supernatant was collected and the reduction of INT was measure at 490 nm.
Body compositions
The amount of protein, lipid, ash and water of the residual carcass was determined by standard gravimetric procedures as previously described. 36 Residual carcass (minus fat pads, BAT, liver and blood) was weighed and then autoclaved for 1 h in 500 ml water. The carcass was then homogenized in a Waring blender for 10 min and the resulting mixture ®ltered over a ®ne screen to remove any undigested hair. An aliquot of this mixture was extracted with chloroform and methanol for the determination of lipid content. Dry matter and ash content were determined by placing a weighed aliquot of the homogenate in an oven at 90 C for 48 h. The remaining sample was weighed to determine the water content lost by drying. Subsequently, the sample was ashed in a muf¯e furnace at 600 C for 12 h and the residue weighed to determine the ash content. The protein content of the homogenate was determined by mass difference (wt of sample 7 [water ash lipid]). This method for determining protein content of rat carcasses has been veri®ed by using the Kjeldahl method.
Serum assays
Serum levels of DHEAS were determined by using a commercial radioimmunoassay (RIA) kit (Wien Laboratories, Inc. Succasunna, NJ). Serum triglycerides were measured using a colorimetric kit (TG-INT #336, Sigma Chemical Co.). Following an acid ethanol extraction and subsequent neutralization of serum, serum IGF-1 levels were determined (generously performed by Dr. Roy Martin, Univ. Georgia) using a double antibody RIA method speci®c for rat IGF-1. Serum insulin levels were measured using a commercially available RIA kit (Linco Research Inc., St Charles, MO) with an antibody made speci®cally against rat insulin.
Statistics
Data were analyzed by one-way analysis of variance 48 using the SuperANOVA program (Abacus Concepts, Berkeley, CA). Differences between treatment means were considered statistically signi®cant at P`0.05.
Results
Food intake, body weight and body composition
Final body weights and body weight gains were similar among all three groups of rats (Table 2) . Moreover, neither level of DHEAS administered in the drinking water signi®cantly altered the food or water intakes of the rats. The weights of the retro-peritoneal, epididymal and inguinal fat pads were less for both DHEAS-treated groups compared to the control group (Figure 1 ). For example, rats administered 10 mg/ml DHEAS had retroperitoneal, inguinal, and epididymal fat pads that were 30, 24 and 21% lighter, respectively, than the corresponding fat pads of the control rats. Furthermore, the total weights of all three pads were less for the DHEAS-treated groups compared to the control group ( Table 2 ). The weights of the fat pads among the DHEAS-treated rats were similar. Liver weight and naso-anal length were not affected by DHEAS treatment. Rats treated with DHEAS has less residual (minus fat pads, liver, BAT and blood) carcass lipid than control rats (Table 3) . Residual carcass water, protein and ash were similar among groups.
Adipose cellularity
The size of the adipocytes in the retroperitoneal and inguinal fat pads were similar among all three groups (Figure 2A ). In contrast, rats administered 100 mg/ml DHEAS (D100) had epididymal adipocytes that were 55% smaller than those of the control rats. Rats treated with DHEAS had fewer adipocytes in all three fat pads ( Figure 2B ). For example, rats administered 10 mg/ml and 100 mg/ml DHEAS had 57 and 75% fewer epididymal adipocytes, respectively, than those of control rats. Rats administered 100 mg/ml DHEAS had fewer epididymal and inguinal adipocytes compared to rats administered 10 mg/ml DHEAS.
Serum parameters
Serum levels of DHEAS in the D10 and D100 groups were approximately 2-and 12-fold higher, respectively, than that of the control group (Table 2) . Serum triglycerides were approximately 50% lower in the DHEAS-treated rats compared to the control rats. IGF-1 levels were higher in both DHEAS-treated groups compared to the control group. Serum insulin levels were similar among all three groups of rats.
Interscapular BAT activity
The weight of the BAT depot (including adhering white adipose tissue) and the concentration of UCP in BAT were greater in DHEAS-treated rats compared to control rats (Table 4) . Although the speci®c activity of Effects of DHEAS on adipose tissue mass and cellularity in rats YR Lea-Currie et al succinate-INT-reductase in BAT increased as the level of DHEAS increased, these differences were not statistically signi®cant.
Discussion
These data demonstrate that growing male SpragueDawley rats administered DHEAS in the drinking water for 14 d had less carcass lipid, lighter fat pads containing fewer adipocytes and lower levels of serum triglycerides than did control rats. Food intake and weight gains were not different among the groups. Plasma levels of DHEAS in the D10 group were approximately twice that of the controls (3.2 AE 0.5 vs 7.1 AE 1.2 ng/ml). No signs of toxicity (hepatomegaly, reduced food intake), androgenicity (aggression, hair loss) or resistance to anesthesia were detected using the lowest level of DHEAS (10 mg/ml or 0.7 mg/ kg body wt/d). However, rats treated with the highest dose of DHEAS (100 mg/ml or 7.0 mg/kg body wt/d) were more aggressive with a tendency to bite and to become easily excited during handling compared to control animals. Plasma levels of DHEAS in the D100 group were about 12-fold higher than the control group. The rats in this group also lost more hair than control or D10 animals. The reason for this hair loss remains unclear. Increased hair loss could be due to more movement in the cage, or an increase in thermogenesis that negated the need for excess hair for body heat maintenance. Treating mice with high levels of DHEA (0.2±0.3% in the diet or 100±200 mg/ kg body wt/d) has been shown to raise serum testosterone levels as high as 25-fold. 42 Unfortunately, we did not measure serum levels of testosterone or other androgens and therefore do not know if the signs of androgenicity we observed in the D100 group were due to increased androgen production.
Although energy intakes were similar among the groups, rats treated with DHEAS had less residual carcass lipid and lighter retroperitoneal, epididymal, and inguinal fat pads compared to control rats. This DHEAS-mediated reduction in fat mass may be due to: (1) blocking adipogenesis (e.g. inhibiting proliferation and/or differentiation), thereby preventing further increases in fat cell number and/or size; or (2) enhancing energy expenditure, thereby increasing lipid turnover (e.g. increasing lipid mobilization and/or decreasing lipid synthesis). In support of the hypothesis concerning adipogenesis, DHEA has been shown to decrease the differentiation of cultures of 3T3L1 cells. These clonal cells are preadipocytes of embryonic murine origin that are capable of differentiating into adipose-like cells. 49, 50 This dose-dependent inhibition of preadipocyte differentiation by DHEA was due in part to the inhibition of glucose-6-phospahte dehydrogenase (G6PD) activity. G6PD is the ®rst The D10 group received 10 mg DHEAS/ml drinking water. c The D100 group received 100 mg DHEAS/ml drinking water. d * to ** means AE s.e.m. within the same row not sharing a common symbol are signi®cantly different (P`0.05).
limiting enzyme of the pentose phosphate shunt, converting glucose-6-phosphate to 6-phosphogluconate. By limiting G6PD activity, DHEA treated preadipocytes would be de®cient in ribose-5-phosphate for nucleic acid synthesis. Furthermore, adipocytes would lack NADPH for fatty acid synthesis. One possible mechanism by which DHEA inhibits G6PD activity and differentiation may be by antagonizing glucocorticoid (dexamethasone) activation of`master' genes that regulate adipogenesis such as CCAATT/ enhancer binding proteins (C/EBP) and peroxisome proliferator-activated receptors (PPARg). 51, 52 These two`master' regulators of the adipogenic program must be activated in order to induce the adipocyte differentiation cascade, 51, 52 including expression of G6PD. Therefore, DHEA may reduce G6PD activity and adipocyte differentiation by antagonizing glucocorticoid induction of adipogenesis.
DHEAS-mediated reductions in adipose tissue mass and cellularity may be due not only to lower rates of adipogenesis, but also to increased turnover of lipid in mature adipocytes. The triglyceride content of adipose tissue is dependent on the balance between lipolysis and lipogenesis. Factors that increase energy expenditure attenuate lipid accumulation by increasing lipolysis and fatty acid oxidation and/or by decreasing lipogenesis. For example, a number of thermogenic agents such as beta-receptor agonists speci®c for white and brown adipose tissue have been tested as antiobesity agents. Himms-Hagen et al 53 recently reported that the drug CL-316,243, a thermogenic beta-3 agonist, signi®cantly reduced carcass fat without altering food intake or adversely affecting heart rate or blood pressure in rats. In addition, the drug increased the mass of brown adipose tissue (BAT) via proliferation while reducing white adipose tissue hyperplasia during the early stage of diet-induced obesity.
Elevations in BAT activity are associated with increased lipolysis, fatty acid oxidation and energy wasting. 53, 54 Like many beta-agonists, DHEA treatment at high levels has been shown to increase metabolic rate, 29, 30, 35 mitochondrial respiration, 25 peroxisomal beta-oxidation 31, 33, 34 and BAT mass. 25 Furthermore, Tagliaferro et al 26 recently found that isoproterenol-stimulated lipolysis in adipocytes isolated from rats fed DHEA (0.4% in the diet) for 4 weeks was 53% greater than in control animals. Therefore, treatment with DHEA may reduce adipose tissue mass by increasing lipolysis, thereby providing fatty acids for thermogenic tissues such as BAT and/ or muscle. 53, 54 In comparison to the studies by Mohan et al 25 and Cleary et al 39 , our rats were fed a high sugar diet (25% sucrose, 25% glucose, w/w) and were administered 500 times less DHEAS (D10 10 mg/ml or approximately 0.7 mg/kg body wt/d) than the DHEA used in their studies. Despite administering 500 times less steroid than Cleary and coworkers, our animals administered 10 mg/ml DHEAS had 25% lighter fat pads and less residual carcass lipid than the control animals after only two weeks of treatment. Furthermore, no obvious signs of toxicity such as hepatomegaly or reduced food intake were observed using this low dose of DHEAS. In support of these ®ndings, Daynes et al 43, 44 demonstrated that treatment with low levels of DHEAS (100 mg/ml drinking water) of aged mice improved immune function without obvious signs of toxicity. However, long term studies using this low level of DHEAS need to be conducted to determine its safety for human use.
In contrast to pharmacological levels of DHEA, we found that fat pad weights of rats are not affected by low levels of DHEA (approximately 1.3±13 mg/kg body wt/d). 24 Sixty male Sprague-Dawley rats, 325 g initial weight, were implanted subcutaneously for 3 weeks with time release pellets containing either DHEA or corticosterone (CORT) at doses of 0, 10, 25, 50, or 100 mg. 24 As the level of each steroid increased, food intake and body weights decreased. Whereas CORT treatment increased the weight of the fat pads and percentage of liver lipid, DHEA treatment had no signi®cant effect on either of these two parameters. Only the rats implanted with the highest dose of DHEA (100 mg pellet or 13 mg/kg body wt/d) had signi®cantly lower serum triglycerides compared to control animals. Although these low levels of DHEA did not cause hepatomegaly or any other obvious signs of toxicity, the primary effect appeared to be on reducing food intake and growth rather than on decreasing body fat itself. Furthermore, feeding rats lower doses of DHEA (for example 0.1% in the diet) does not appear to reduce body fat levels in rats. 26 Hence most investigators 8±10 administer high levels of DHEA (200±400 mg/kg body wt/d) to elicit a decrease in body fat in animals.
These observations raise the question as to why DHEAS is more effective at low doses than DHEA in reducing adipocyte mass and cellularity? DHEAS is the most abundant steroid in the plasma of humans and rodents. However, DHEAÐnot DHEASÐis the receptor active form of the steroid. The lipophilic nature of DHEA allows it to diffuse across most cell membranes without target tissue speci®city. On the other hand, DHEAS is hydrophilic and therefore must be transported into target tissues via tissue-speci®c transport mechanisms. For example, DHEAS has been shown to be transported into hepatocytes by an energy-dependent, carrier mediated process. 55 It is not known whether adipoctyes have a speci®c transport carrier system for DHEAS. However, it is known that numerous tissues such as gonads, lung, liver, and adipose contain steroid sulfates that convert DHEAS to DHEA. 5 Moreover, human and rat adipocytes readily metabolize DHEA. 3, 4, 6 The much longer half-life of DHEAS in circulation compared to DHEA 3 may contribute to its greater potency and effectiveness in preventing or reversing adiposity in rats. Lastly, when given orally, DHEA would be absorbed via the lymphatics whereas DHEAS would enter the portal system. This difference in route of entry into systemic circulation may impact the subsequent metabolism of the steroid. Therefore, compared to DHEA, DHEAS may: (1) be more readily absorbed into systemic circulation following administration, (2) have a greater potency due to its longer half-life, or (3) be speci®cally transported more ef®ciently in certain target tissues compared to DHEA, which readily diffuses into most tissues.
In summary, administration of low levels of DHEAS in the drinking water of male rats decreased body fat, the number of adipocytes in the three major fat depots, and serum triglcyerides without signi®-cantly affecting food intake or body weight gain. No obvious signs of toxicity (hepatomegaly) were observed for the DHEAS-treated rats. It remains unclear why DHEAS is more effective at lower doses than DHEA in reducing adipocyte mass and cellularity in rats. Future studies examining whether DHEAS decreases adipogenesis and/or increases lipid turnover, would provide insight into the mechanism of action of DHEAS. Measuring serum metabolites of DHEAS following treatment would help identify the active agent affecting fat cell growth and metabolism, vis-a-vis, DHEAS, DHEA or some downstream metabolite.
